Key points are not available for this paper at this time.
In patients with relapsing remitting multiple sclerosis (RRMS) on low-efficacy disease modifying therapies (DMT), the optimal strategy on how to escalate treatment once needed, remains unknown.
Müller et al. (2024) studied this question.